Related Experiment Videos
Impact of Using Biomarkers in Eligibility Criteria in Acute Kidney Injury Randomized Controlled Trials: A Systematic
Fella Chennou1,2, Michael Strader3, Roxanne Authier1
1Université de Montréal, Montreal, QC, Canada.
Kidney Medicine
|July 25, 2026
Summary
Biomarker enrichment in acute kidney injury trials may inflate event rates and reduce statistical power. Rigorous biomarker validation is crucial before clinical trial implementation to ensure accurate outcomes.
Area of Science:
- Nephrology
- Clinical Trials
- Biomarker Research
Background:
- Randomized controlled trials (RCTs) for acute kidney injury (AKI) increasingly use biomarkers for eligibility criteria.
- Sample size calculations in these trials often rely on data from studies without biomarker enrichment.
- This discrepancy may affect the reliability of trial outcomes and statistical power.
Purpose of the Study:
- To evaluate the impact of biomarker-based enrichment strategies on event rates in AKI RCTs.
- To assess the effect of biomarker integration on the statistical power of these trials.
- To compare anticipated versus observed primary event rates in AKI clinical studies.
Main Methods:
- A PRISMA-guided systematic review and meta-analysis of RCTs published between 2010 and 2023.
- Included trials focused on patients with AKI and utilized biomarker-based eligibility criteria.
- Analyzed the absolute risk difference between anticipated and observed event rates and statistical power.
Main Results:
- Fourteen RCTs with 3,817 patients were analyzed, examining biomarkers like NGAL, TIMP-2*IGFBP7, and others.
- A pooled absolute risk difference of 0.12 (95% CI, 0.06-0.17) was observed between anticipated and actual event rates.
- Mean preplanned statistical power (0.84) was significantly higher than achieved power (0.43), with no improvement from sample size extrapolation.
Conclusions:
- Biomarker enrichment in AKI RCTs may contribute to a discrepancy between expected and observed event rates.
- Most included RCTs were underpowered for their primary outcomes, indicating potential issues with trial design.
- Emphasizes the necessity for robust biomarker validation prior to their use in clinical trial eligibility criteria.
Related Concept Videos
01:22Acute Kidney Injury I: Introduction
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
01:29Acute Kidney Injury II: Pathophysiology
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
01:17Factors Affecting Renal Clearance: Renal Impairment
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...